Literature DB >> 8666947

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.

G Nussbaum1, R Yuan, A Casadevall, M D Scharff.   

Abstract

Vaccination and infection can elicit protective and nonprotective antibodies to the fungus Cryptococcus neoformans in mice. The effect of nonprotective antibodies on host defense is unknown. In this study we used mixtures of protective and nonprotective monoclonal antibodies (mAbs) to determine if nonprotective mAbs blocked the activity of the protective mAbs. Antibody isotype and epitope specificity are important in determining the ability to prolong survival in mice given a lethal C. neoformans infection. Three different nonprotective immunoglobulin (Ig) G23 mAbs to cryptococcal capsular polysaccharide were used to study the interaction between the IgG3 isotype and protective IgG1 and IgG2a mAbs in murine cryptococcal infection. One IgG3 mAb reduced the protective efficacy of an IgG1 with identical epitope specificity. A second IgG3 mAb with different epitope specificity also reduced the protection provided by the IgG1 mAb. The protective efficacy of an IgG2a mAb was also dramatically decreased by still another IgG3 mAb. To our knowledge this is the first report of blocking antibodies to a fungal pathogen. The results have important implications for the development of vaccines and passive antibody therapy against C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666947      PMCID: PMC2192512          DOI: 10.1084/jem.183.4.1905

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae.

Authors:  K A Joiner; R Scales; K A Warren; M M Frank; P A Rice
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

2.  Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae.

Authors:  D E Briles; J L Claflin; K Schroer; C Forman
Journal:  Nature       Date:  1981-11-05       Impact factor: 49.962

3.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

4.  Passive immunization in murine cryptococcosis.

Authors:  J R Graybill; M Hague; D J Drutz
Journal:  Sabouraudia       Date:  1981-12

5.  In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.

Authors:  S B Halstead
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

6.  Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection.

Authors:  R M Guttman; B A Waisbren
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

7.  The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.

Authors:  T R Kozel; E C Gotschlich
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

8.  Genetic control of susceptibility to Cryptococcus neoformans in mice.

Authors:  J C Rhodes; L S Wicker; W J Urba
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Antibody response that protects against disseminated candidiasis.

Authors:  Y Han; J E Cutler
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency.

Authors:  J Slack; G P Der-Balian; M Nahm; J M Davie
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

View more
  25 in total

Review 1.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

2.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniae.

Authors:  S L Harris; M K Park; M H Nahm; B Diamond
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.

Authors:  R R Yuan; G Spira; J Oh; M Paizi; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

Review 5.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

6.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 7.  Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

8.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis.

Authors:  Daniela de Mattos Grosso; Sandro Rogério de Almeida; Mario Mariano; Jose Daniel Lopes
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies.

Authors:  Siu-Kei Chow; Cameron Smith; Thomas MacCarthy; Mary Ann Pohl; Aviv Bergman; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.